As fears of recession loom, the consumer price index up 6.5 percent and inflation at historic highs, funds that Americans saved during the COVID-19 pandemic are nearing depletion.
During the height of the pandemic, Americans were able to save more than $2.7 trillion as businesses shuttered. Investment bank Goldman Sachs estimated that 35 percent of COVID-19 relief funds have already been spent and by the end of 2023, that number will be up to 65 percent.
Lower income households have seen their savings diminish first. Folks that make under $50,000 annually saw their savings slashed by 36 percent compared to people who make between $100,000 and 15,000 who lost just 14 percent of their savings.
The use of credit has surged during this time as well, pushing the credit card debt to a new record of more than $930 billion at the end of 2022. It's a jump of 18 percent from the previous year.
Meanwhile, Treasury Secretary Janet Yellen rejected concerns that the U.S. isn't headed for a recession and believes that inflation can be eased.
"You don't have a recession when you have 500,000 jobs and the lowest unemployment rate in more than 50 years. What I see is a path in which inflation is declining significantly, and the economy is remaining strong," she said in an interview with ABC's Good Morning America.
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
